Curiox BioSystems
Financials
Valuation Metrics
Curiox BioSystems's Market Cap is ₩7217B. At end of 2025 it was ₩2.0T. Ranked #355 of 2,436 in KR market (top 15%), #110 of 1,649 on KOSDAQ (top 7%), #39 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 17%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 721.68B KRW | KR#355/2,436 Sec#39/234 |
| Revenue | 5.55B KRW | KR#2,339/2,436 Sec#194/234 |
| Net Income | -26.20B KRW | KR—/2,436 Sec—/234 |
| Total Assets | 77.73B KRW | KR#1,925/2,436 Sec#161/234 |
| Net Assets | 51.72B KRW | KR#1,850/2,436 Sec#159/234 |
| Employees | 23 | KR#2,214/2,436 Sec#206/234 |
| Value | ||
| P/B | 13.95x | KR#2,373/2,436 Sec#215/234 |
| P/S | 129.93x | KR#2,396/2,436 Sec#215/234 |
| FCF Yield | -1.56% | KR—/2,436 Sec—/234 |
| Profitability | ||
| ROE | -50.66% | KR#2,270/2,436 Sec#200/234 |
| ROA | -33.71% | KR#2,320/2,436 Sec#207/234 |
| Op. Margin | -225.80% | KR#2,347/2,436 Sec#190/234 |
| Revenue Growth | 43.72% | KR#338/2,436 Sec#32/234 |
| Earnings Growth | -1735.60% | KR#1,716/2,436 Sec#118/234 |
| Financial Health | ||
| Debt Ratio | 150.29% | KR#1,188/2,436 Sec#138/234 |
| Total Debt | 1.94B KRW | KR#1,902/2,436 Sec#184/234 |
| FCF | -11.25B KRW | KR#1,749/2,436 Sec#155/234 |
| Cash | 10.06B KRW | KR#1,669/2,436 Sec#134/234 |
| Current Ratio | 1.59x | KR#1,244/2,436 Sec#136/234 |
| Performance | ||
| 1Y Return | 1.08% | KR#692/2,436 Sec#54/234 |
| 1M Return | -0.24% | KR#903/2,436 Sec#81/234 |
| From 52W High | -71.88% | KR#2,197/2,436 Sec#202/234 |
| 1Y MDD | -75.43% | KR#2,165/2,436 Sec#197/234 |
| Trading | ||
| Volume | 111,282 shares | KR#879/2,436 Sec#88/234 |
| Foreign Own. | 8.75% | KR#516/2,436 Sec#44/234 |
| Per Share | ||
| EPS | -1,563 KRW | KR—/2,436 Sec—/234 |
| BPS | 3,021 KRW | KR#1,812/2,436 Sec#141/234 |
Company Info
Curiox Biosystems was established in 2018 to commercialize cell analysis process automation technology, developing a global sales network via subsidiaries in the United States, China, and Singapore. The company sells automated cell pre-processing equipment, plates, and accessories, featuring its unique Curiox C-FREE™ technology that significantly improves automation, data accuracy, and reproducibility in cell analysis. This non-centrifuge-based automated cell pre-processing product grants it a distinctive market position. Curiox Biosystems is headquartered in Geumcheon-gu, Seoul Metropolitan City.